Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) EPS (Weighted Average and Diluted) (2021 - 2026)

Envoy Medical's EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.08 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 72.41% to -$0.08 in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.01, a 26.28% increase, with the full-year FY2025 number at -$1.23, up 17.45% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.08 in Q1 2026 for Envoy Medical, up from -$0.26 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for COCH hit a ceiling of $0.23 in Q1 2022 and a floor of -$1.31 in Q1 2023.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.3 across 5 years, with a median of -$0.29 in 2024.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 200.0% in 2023, down 669.57% in 2023.
  • Tracing COCH's EPS (Weighted Average and Diluted) over 5 years: stood at -$1.13 in 2022, then surged by 92.92% to -$0.08 in 2023, then crashed by 400.0% to -$0.4 in 2024, then soared by 35.0% to -$0.26 in 2025, then soared by 69.23% to -$0.08 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for COCH at -$0.08 in Q1 2026, -$0.26 in Q4 2025, and -$0.35 in Q3 2025.